<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ESTRACE- estradiolÂ tabletÂ </strong><br>Warner Chilcott (US), LLC<br></p></div>
<h1>ESTRACE<span class="Sup">Â®</span>Â  TABLETS<br>(estradiol tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49251a0c-6f50-4b7c-b156-0af57d2a7f00"></a><a name="section-1"></a><p></p>
<p class="First">720<br>721<br>722</p>
<p>11001648</p>
<p><span class="Bold">Rx only</span></p>
<div class="Warning">
<a name="id_e2253273-9537-438c-a6a4-45dbd79f7051"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold">ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER</span></p>
<p>Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of â€œnaturalâ€? estrogens  results in a different endometrial risk profile than â€œsyntheticâ€? estrogens at  equivalent estrogen doses. (See <span class="Bold">WARNINGS, Malignant neoplasms, </span><span class="Italics">Endometrial cancer</span>.)</p>
<p><span class="Bold">CARDIOVASCULAR AND OTHER RISKS</span></p>
<p>Estrogens with or without progestins should not be used for the prevention of cardiovascular disease. (See <span class="Bold"><a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span></a></span>.) </p>
<p>The Womenâ€™s Health Initiative (WHI) study reported increased risks of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, invasive breast cancer, pulmonary emboli, and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies.</a></span>)</p>
<p>The Womenâ€™s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo.  It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy.  (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies</a>.</span>)</p>
<p>Other doses of oral conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar.  Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_7be298e6-e66c-4e0a-a57b-5b1f3c1263af"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">ESTRACE<span class="Sup">Â®</span> (estradiol tablets, USP) for oral administration contains 0.5, 1 or 2 mg of micronized estradiol per tablet. Estradiol (17ÃŸ-estradiol) is a white, crystalline solid, chemically described as estra-1,3,5,(10)-triene-3, 17ÃŸ-diol. The structural formula is:</p>
<div class="Figure"><img alt="structual formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc&amp;name=049c9f13-fc5b-417b-b686-403f17052eae-01.jpg"></div>
<p><span class="Bold">Inactive Ingredients:</span> Colloidal silicon dioxide, corn starch, dibasic calcium phosphate, lactose monohydrate, magnesium stearate, and sodium starch glycolate. In addition, the 1 mg also contains FD&amp;C blue no. 1 aluminum lake and D&amp;C red no. 27 aluminum lake. The 2 mg also contains FD&amp;C blue no. 1 aluminum lake and FD&amp;C yellow no. 5 (tartrazine) aluminum lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. </p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone by peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. </p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.</p>
<p>Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_b8223a8f-e66c-45fa-8bec-bd5100d3c4f7"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics:</h2>
<p class="First"><span class="Bold">Â </span></p>
<p><span class="Bold"><span class="Italics">Distribution:</span></span></p>
<p>The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
<p><span class="Italics"><span class="Bold">Metabolism:</span></span></p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. </p>
<p><span class="Italics"><span class="Bold">Excretion:</span></span></p>
<p>Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates.</p>
<p><span class="Italics"><span class="Bold">Special Populations:</span></span></p>
<p>No pharmacokinetic studies were conducted in special populations, including patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Italics"><span class="Bold">Drug Interactions:</span></span></p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. Johnâ€™s Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and mayÂ  result in side effects.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7"></a><a name="section-3.2"></a><p></p>
<h2>Clinical Studies:</h2>
<p class="First"><span class="Italics"><span class="Bold"><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span>:</span></span></p>
<p>Most prospective studies of efficacy for this indication have been carried out in white menopausal women, without stratification by other risk factors, and tend to show a universally salutary effect on bone. </p>
<p>The results of a two-year, randomized, placebo-controlled, double-blind, dose-ranging study have shown that treatment with 0.5 mg estradiol daily for 23 days (of a 28 day cycle) prevents vertebral bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> loss in postmenopausal women. When estrogen therapy is discontinued, bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> declines at a rate comparable to the immediate postmenopausal period. There is no evidence that estrogen replacement therapy restores bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> to premenopausal levels.</p>
<p><span class="Italics"><span class="Bold">Women's Health Initiative Studies:</span></span></p>
<p>The Womenâ€™s Health Initiative (WHI) enrolled a total of 27,000 predominantly healthy postmenopausal women to assess the risks and benefits of either the use of oral 0.625 mg conjugated estrogens (CE) per day alone or the use of oral 0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate (MPA) per day compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of coronary heart disease (CHD) (nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome studied. A â€œglobal indexâ€? included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. The study did not evaluate the effects of CE or CE/MPA on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>. </p>
<p>The CE/MPA substudy was stopped early because, according to the predefined stopping rule, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the â€œglobal index.â€? Results of the CE/MPA substudy, which included 16,608 women (average age of 63 years, range 50 to 79; 83.9% White, 6.5% Black, 5.5% Hispanic), after an average follow-up of 5.2 years are presented in Table 1 below:</p>
<p><span class="Bold">Table 1: RELATIVE AND ABSOLUTE RISK SEEN IN THE CE/MPA SUBSTUDY OF WHI<span class="Sup">a</span></span></p>
<a name="id_8ba80eef-3e9a-4dc0-8ddb-bd5b288b8bb8"></a><table border="single" width="432.000">
<col width="25.0%">
<col width="25.0%">
<col width="25.0%">
<col width="25.0%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="top">Event<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="left" rowspan="2" valign="top">
<p class="First">Relative Risk <br>CE/MPA vs placebo<br> at 5.2 Years</p>(95% CI<span class="Sup">*</span>)</td>
<td class="Botrule Rrule" align="center" valign="top">Placebo<br>n = 8102</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">CE/MPA</p>n = 8506</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"><p class="First">Absolute Risk per 10,000 Women-years</p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">CHD events<br><span class="Italics">Non-fatal MI<br> CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.29 (1.02-1.63)<br><span class="Italics">1.32 (1.02-1.72)<br>1.18 (0.70-1.97)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Italics">30<br>23<br>6</span></td>
<td class="Botrule Rrule" align="center" valign="top">37<br><span class="Italics">30<br>7</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Invasive breast cancer<span class="Sup">b</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.26 (1.00-1.59)</td>
<td class="Botrule Rrule" align="center" valign="top">30</td>
<td class="Botrule Rrule" align="center" valign="top">38</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></td>
<td class="Botrule Rrule" align="left" valign="top">1.41 (1.07-1.85)</td>
<td class="Botrule Rrule" align="center" valign="top">21</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></td>
<td class="Botrule Rrule" align="left" valign="top">2.13 (1.39-3.25)</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Colorectal cancer</td>
<td class="Botrule Rrule" align="left" valign="top">0.63 (0.43-0.92)</td>
<td class="Botrule Rrule" align="center" valign="top">16</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Endometrial cancer</td>
<td class="Botrule Rrule" align="left" valign="top">0.83 (0.47-1.47)</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span></td>
<td class="Botrule Rrule" align="left" valign="top">0.66 (0.45-0.98)</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to causes other than the events above</td>
<td class="Botrule Rrule" align="left" valign="top">0.92 (0.74-1.14)</td>
<td class="Botrule Rrule" align="center" valign="top">40</td>
<td class="Botrule Rrule" align="center" valign="top">37</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Global Index<span class="Sup">c</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.15 (1.03-1.28)</td>
<td class="Botrule Rrule" align="center" valign="top">151</td>
<td class="Botrule Rrule" align="center" valign="top">170</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">2.07 (1.49-2.87)</td>
<td class="Botrule Rrule" align="center" valign="top">13</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><span class="Sup">d</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">0.66 (0.44-0.98)</td>
<td class="Botrule Rrule" align="center" valign="top">15</td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Other <span class="product-label-link" type="condition" conceptid="4188189" conceptname="Osteoporotic fracture">osteoporotic fractures</span><span class="Sup">d</span>
</td>
<td class="Rrule" align="left" valign="top">0.77 (0.69-0.86)</td>
<td class="Rrule" align="center" valign="top">170</td>
<td class="Botrule Rrule" align="center" valign="top">131</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>adapted from JAMA, 2002; 288:321-333<br><span class="Sup">b</span>includes metastatic and non-metastatic breast cancer with the exception of <span class="Italics">in situ</span> breast cancer</p>
<p><span class="Sup">c</span>a subset of the events was combined in a â€œglobal indexâ€?, defined as the earliest occurrence of CHD events,</p>
<p>invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes</p>
<p><span class="Sup">d</span>not included in Global Index<br>*nominal confidence intervals unadjusted for multiple looks and multiple comparisons</p>
<p>For those outcomes included in the â€œglobal index,â€? the absolute excess risks per 10,000 women-years in the group treated with CE/MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 8 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the â€œglobal indexâ€? was 19 per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality. (See <span class="Bold">BOXED WARNINGS, <a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS</a>, </span>and<span class="Bold"><a href="#i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc"> PRECAUTIONS</a></span>.)</p>
<p><span class="Bold"><span class="Italics">Women's Health Initiative Memory Study:</span></span></p>
<p>The Womenâ€™s Health Initiative Memory Study (WHIMS), a substudy of WHI, enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47% were age 65 to 69 years, 35% were 70 to 74 years, and 18% were 75 years of age and older) to evaluate the effects of CE/MPA (0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared with placebo.</p>
<p>After an average follow-up of 4 years, 40 women in the estrogen/progestin group (45 per 10,000 women-years) and 21 in the placebo group (22 per 10,000 women-years) were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the hormone therapy group was 2.05 (95% CI, 1.21 to 3.48) compared to placebo. Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women. (See <span class="Bold">BOXED WARNING</span> and <span class="Bold"><a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>.</a></span>)</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f226f7bb-c7be-4614-8e88-3f208296ba33"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">ESTRACE (estradiol tablets, USP) is indicated in the:</p>
<ol>
<li>Treatment of moderate to severe vasomotor symptoms associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</li>
<li>Treatment of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. When prescribing solely for the treatment of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.</li>
<li>Treatment of hypoestrogenism due to <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>, castration or <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">primary ovarian failure</span>.</li>
<li>Treatment of breast cancer (for palliation only) in appropriately selected women and men with <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</li>
<li>Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).</li>
<li>Prevention of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should only be considered for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and for whom non-estrogen medications are not considered to be appropriate. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a></span>, <span class="Bold"><a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies</a></span>.)<br>The mainstays for decreasing the risk of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500Â mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_5fa06a4b-3a3b-4866-a17d-aa172171348b"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Estrogens should not be used in individuals with any of the following conditions:</p>
<ol>
<li>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Known, suspected or history of cancer of the breast except in appropriately selected patients being treated for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</li>
<li>Known or suspected estrogen-dependent neoplasia.</li>
<li>Active <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or history of these conditions.</li>
<li>Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>).</li>
<li>Liver dysfunction or disease.</li>
<li>ESTRACE should not be used in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to its ingredients. ESTRACE (estradiol tablets, USP), 2 mg, contain FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible individuals. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</li>
<li>Known or suspected pregnancy. There is no indication for ESTRACE in pregnancy. There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (See<span class="Bold"><a href="#i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc"> PRECAUTIONS.</a></span>)</li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4"></a><a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">See <span class="Bold">BOXED WARNINGS.</span></p>
<p><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span>.</span></p>
<p>Estrogen and estrogen/progestin therapy has been associated with an increased risk of cardiovascular events such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, as well as <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (<span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> or VTE). Should any of these occur or be suspected, estrogens should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (e.g., personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<p><span class="Italics"><span class="Bold">a. Coronary heart disease and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span></span></p>
<p>In the Womenâ€™s Health Initiative (WHI) study, an increase in the number of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing<span class="Italics">.</span> (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies</a></span>.)</p>
<p>In the CE/MPA substudy of WHI, an increased risk of coronary heart disease (CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was observed in women receiving CE/MPA compared to women receiving placebo (37 vs 30 per 10,000 person years). The increase in risk was observed in year one and persisted.</p>
<p>In the same substudy of WHI, an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed in women receiving CE/MPA compared to women receiving placebo (29 vs 21 per 10,000 women-years). The increase in risk was observed after the first year and persisted.</p>
<p>In postmenopausal women with documented heart disease (n = 2,763, average age 66.7 years) a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study; HERS) treatment with CE/MPA (0.625 mg/2.5 mg per day) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE/MPA did not reduce the overall rate of CHD events in postmenopausal women with established coronary heart disease. There were more CHD events in the CE/MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand three hundred and twenty one women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE/MPA group and the placebo group in HERS, HERS II, and overall.</p>
<p>Large doses of estrogen (5 mg conjugated estrogens per day), comparable to those used to treat cancer of the prostate and breast, have been shown in a large prospective clinical trial in men to increase the risks of nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>.</p>
<p><span class="Italics"><span class="Bold">b.<span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span> (VTE).</span></span></p>
<p>In the Womenâ€™s Health Initiative (WHI) study, an increase in VTE has been observed in women receiving CE compared to placebo. These observations are preliminary, and the study is continuing. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies</a></span>.) </p>
<p>In the CE/MPA substudy of WHI, a 2Â­fold greater rate of VTE, including deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, was observed in women receiving CE/MPA compared to women receiving placebo. The rate of VTE was 34 per 10,000 womenÂ­years in the CE/MPA group compared to 16 per 10,000 womenÂ­years in the placebo group. The increase in VTE risk was observed during the first year and persisted.</p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization.</p>
<p><span class="Bold">2. Malignant neoplasms.</span></p>
<p><span class="Italics"><span class="Bold">a. Endometrial cancer.</span></span></p>
<p>The use of unopposed estrogens in women with intact uteri has been associated with an increased risk of endometrial cancer. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12- fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than one year. The greatest risk appears associated with prolonged useâ€”with increased risks of 15- to 24-fold for five to ten years or moreâ€”and this risk persists for 8 to over 15 years after estrogen therapy is discontinued. </p>
<p>Clinical surveillance of all women taking estrogen/progestin combinations is important (see <span class="Bold"><a href="#i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc">PRECAUTIONS)</a></span>. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. </p>
<p><span class="Italics"><span class="Bold">b. Breast cancer.</span></span></p>
<p>The use of estrogens and progestins by postmenopausal women has been reported to increase the risk of breast cancer. The most important randomized clinical trial providing information about this issue is the Womenâ€™s Health Initiative (WHI) substudy of CE/MPA (see <span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a></span>, <span class="Bold"><a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies</a></span>). The results from observational studies are generally consistent with those of the WHI clinical trial and report no significant variation in the risk of breast cancer among different estrogens or progestins, doses, or routes of administration.</p>
<p>The CE/MPA substudy of WHI reported an increased risk of breast cancer in women who took CE/MPA for a mean follow-up of 5.6 years. Observational studies have also reported an increased risk for estrogen/progestin combination therapy, and a smaller increased risk for estrogen alone therapy, after several years of use. In the WHI trial and from observational studies, the excess risk increased with duration of use. From observational studies, the risk appeared to return to baseline in about five years after stopping treatment. In addition, observational studies suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen/progestin combination therapy as compared to estrogen alone therapy. </p>
<p>In the CE/MPA substudy, 26% of the women reported prior use of estrogen alone and/or estrogen/progestin combination hormone therapy. After a mean follow-up of 5.6 years during the clinical trial, the overall relative risk of invasive breast cancer was 1.24 (95% confidence interval 1.01-1.54), and the overall absolute risk was 41 vs 33 cases per 10,000 women-years, for CE/MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86, and the absolute risk was 46 vs 25 cases per 10,000 women-years, for CE/MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09, and the absolute risk was 40 vs 36 cases per 10,000 women-years for CE/MPA compared with placebo. In the same substudy, invasive breast cancers were larger and diagnosed at a more advanced stage in the CE/MPA group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare with no apparent difference between the two groups. Other prognostic factors such as histologic subtype, grade and hormone receptor status did not differ between the groups. </p>
<p>The use of estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span>.</span></p>
<p>In the Womenâ€™s Health Initiative Memory Study (WHIMS), 4,532 generally healthy postmenopausal women 65 years of age and older were studied, of whom 35% were 70 to 74 years of age and 18% were 75 or older. After an average follow-up of 4 years, 40 women being treated with CE/MPA (1.8%, n = 2,229) and 21 women in the placebo group (0.9%, n = 2,303) received diagnoses of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk for CE/MPA versus placebo was 2.05 (95% confidence interval 1.21 â€“ 3.48), and was similar for women with and without histories of menopausal hormone use before WHIMS. The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE/MPA versus placebo was 45 versus 22 cases per 10,000 women-years, and the absolute excess risk for CE/MPA was 23 cases per 10,000 women-years. It is unknown whether these findings apply to younger postmenopausal women. (See<span class="Bold"><a href="#i4i_clinical_pharmacology_id_f828da6c-33e6-46ae-b3de-9c83d14d523f">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_clinical_studies_id_80a15fb0-9330-4224-aebe-2d9c604d0dd7">Clinical Studies</a></span>and <span class="Bold"><a href="#i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc">PRECAUTIONS, Geriatric Use.</a></span><span class="Bold">)</span></p>
<p>It is unknown whether these findings apply to estrogen alone therapy.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span>.</span></p>
<p>A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
<p><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span>.</span></p>
<p>Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in patients with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.</p>
<p><span class="Bold">6. Visual abnormalities.</span></p>
<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First"><span class="Bold">A. General:</span></p>
<p><span class="Bold">1.<span class="Italics"> Addition of a progestin when a woman has not had a hysterectomy.</span></span></p>
<p>Studies of the addition of a progestin for 10 or more days of a cycle of estrogen administration, or daily with estrogen in a continuous regimen, have reported a lowered incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> than would be induced by estrogen treatment alone. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer.</p>
<p>There are, however, possible risks which may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include a possible increased risk of breast cancer. </p>
<p><span class="Bold">2.<span class="Italics"> Elevated blood pressure.</span></span></p>
<p>In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogens on blood pressure was not seen. Blood pressure should be monitored at regular intervals with estrogen use.</p>
<p><span class="Bold">3.<span class="Italics"> <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span>.</span></span></p>
<p>In patients with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and other complications. </p>
<p><span class="Bold">4.<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">Impaired liver function</span> and past history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</span></span></p>
<p>Estrogens may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued.</p>
<p><span class="Bold">5.<span class="Italics"> <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span>.</span></span></p>
<p>Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Patients with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Patients dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These patients should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
<p><span class="Bold">6.<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span>.</span></span></p>
<p>Because estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, patients with conditions that might be influenced by this factor, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, and cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.</p>
<p><span class="Bold">7.<span class="Italics"> <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span>.</span></span></p>
<p>Estrogens should be used with caution in individuals with severe <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>.</p>
<p><span class="Bold">8.<span class="Italics"> Ovarian cancer.</span></span></p>
<p>The CE/MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE/MPA versus placebo was 1.58 (95% confidence interval 0.77 â€“ 3.24) but was not statistically significant. The absolute risk for CE/MPA versus placebo was 4.2 versus 2.7 cases per 10,000 women-years. In some epidemiologic studies, the use of estrogen alone, in particular for ten or more years, has been associated with an increased risk of ovarian cancer. Other epidemiologic studies have not found these associations. </p>
<p><span class="Bold">9.<span class="Italics"> Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>.</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens. A few cases of malignant transformation of residual endometrial implants have been reported in women treated post-hysterectomy with estrogen alone therapy. For patients known to have residual <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span> post-hysterectomy, the addition of progestin should be considered.</p>
<p><span class="Bold">10.<span class="Italics"> Exacerbation of other conditions</span></span><span class="Italics">.</span></p>
<p>Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
<p>ESTRACE (estradiol tablets, USP), 2 mg, contain FD&amp;C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible individuals. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<p><span class="Bold">B. Patient Information:</span></p>
<p>Physicians are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe ESTRACE.</p>
<p><span class="Bold">C. Laboratory Tests:</span></p>
<p>Estrogen administration should be initiated at the lowest dose approved for the indication and then guided by clinical response rather than by serum hormone levels (e.g., estradiol, FSH). (See <span class="Bold"><a href="#i4i_dosage_admin_id_0517fb40-9590-4483-ab14-d0559add54b8">DOSAGE AND ADMINISTRATION</a></span> section.)</p>
<p><span class="Bold">D. Drug/Laboratory Test Interactions:</span></p>
<ol>
<li>Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</li>
<li>Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> levels (by column or by radioimmunoassay) or T<span class="Sub">3</span> levels by radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.</li>
<li>Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</li>
<li>Increased plasma HDL and HDL<span class="Sub">2</span> subfraction concentrations, reduced LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglycerides levels.</li>
<li>Impaired glucose tolerance.</li>
<li>Reduced response to metyrapone test.<p class="First"></p>
</li>
</ol>
<p><span class="Bold">E. Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></p>
<p>Long-term continuous administration of estrogen, with and without progestin, in women with and without a uterus, has shown an increased risk of endometrial cancer, breast cancer, and ovarian cancer. (See <span class="Bold">BOXED WARNINGS, <a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS</a></span>and <span class="Bold"><a href="#i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc">PRECAUTIONS</a></span>.)</p>
<p>Long term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. </p>
<p><span class="Bold">F. Pregnancy Category X:</span></p>
<p>Estrace should not be used during pregnancy. (See <span class="Bold"><a href="#i4i_contraindications_id_5fa06a4b-3a3b-4866-a17d-aa172171348b">CONTRAINDICATIONS</a></span>.<span class="Bold">)</span></p>
<p><span class="Bold">G. Nursing Mothers:</span></p>
<p>Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving this drug. Caution should be exercised when ESTRACE is administered to a nursing woman.</p>
<p><span class="Bold">H. Pediatric Use:</span></p>
<p>Safety and effectiveness in pediatric patients have not been established. Large and repeated doses of estrogen over an extended period of time have been shown to accelerate epiphyseal closure, resulting in short adult stature if treatment is initiated before the completion of physiologic puberty in normally developing children. In patients in whom bone growth is not complete, periodic monitoring of bone maturation and effects on epiphyseal centers is recommended.</p>
<p>Estrogen treatment of prepubertal children also induces premature breast development and vaginal cornification, and may potentially induce <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> in girls. In boys, estrogen treatment may modify the normal pubertal process. All other physiological and adverse reactions shown to be associated with estrogen treatment of adults could potentially occur in the pediatric population, including thromboembolic disorders and growth stimulation of certain tumors. Therefore, estrogens should only be administered to pediatric patients when clearly indicated and the lowest effective dose should always be utilized.</p>
<p><span class="Bold">I. Geriatric Use:</span></p>
<p>The safety and efficacy of ESTRACE tablets in geriatric patients has not been established. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greatest frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>In the Womenâ€™s Health Initiative Memory Study, including 4,532 women 65 years of age and older, followed for an average of 4 years, 82% (n = 3,729) were 65 to 74 while 18% (n = 803) were 75 and over. Most women (80%) had no prior hormone therapy use. Women treated with conjugated estrogens plus medroxyprogesterone acetate were reported to have a two-fold increase in the risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Alzheimerâ€™s disease was the most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in both the conjugated estrogens plus medroxyprogesterone acetate group and the placebo group. Ninety percent of the cases of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> occurred in the 54% of women that were older than 70. (See<span class="Bold"><a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></span>.<span class="Bold">)</span></p>
<p>It is unknown whether these findings apply to estrogen alone therapy.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_d476ef53-1d07-4e34-8ec6-52e73f836bc0"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">See <span class="Bold">BOXED WARNINGS, <a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS</a></span>, and <span class="Bold"><a href="#i4i_precautions_id_5850fd6f-e427-46bd-b36d-d03a0ddefebc">PRECAUTIONS</a></span>.</p>
<p>The following additional adverse reactions have been reported with estrogen and/or progestin therapy.</p>
<p><span class="Bold">1. Genitourinary system</span></p>
<p>Changes in <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> pattern and abnormal <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> or flow; breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, spotting, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> </p>
<p>Increase in size of uterine leiomyomata </p>
<p><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span>, including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> </p>
<p>Change in amount of cervical secretion </p>
<p>Changes in cervical <span class="product-label-link" type="condition" conceptid="376132" conceptname="Ectropion">ectropion</span></p>
<p>Ovarian cancer; <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>; endometrial cancer</p>
<p><span class="Bold">2. Breasts</span></p>
<p><span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span>, enlargement, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>; <span class="product-label-link" type="condition" conceptid="78804" conceptname="Fibrocystic disease of breast">fibrocystic breast</span> changes; breast cancer</p>
<p><span class="Bold">3. Cardiovascular</span></p>
<p>Deep and superficial <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>; <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>; increase in blood pressure</p>
<p><span class="Bold">4. Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></p>
<p><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span></p>
<p>Increased incidence of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span></p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span></p>
<p>Enlargement of hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span></p>
<p><span class="Bold">5. Skin</span></p>
<p><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Chloasma</span> or <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">melasma</span> that may persist when drug is discontinued </p>
<p><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span></p>
<p><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span></p>
<p>Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span></p>
<p>Loss of scalp hair</p>
<p><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></p>
<p><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Bold">6. Eyes</span></p>
<p>Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span></p>
<p>Steepening of corneal curvature</p>
<p>Intolerance to contact lenses</p>
<p><span class="Bold">7. Central Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p>
<p><span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">Chorea</span> </p>
<p><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, mood disturbances, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></p>
<p>Exacerbation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span></p>
<p><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></p>
<p><span class="Bold">8. Miscellaneous</span></p>
<p>Increase or decrease in weight</p>
<p>Reduced carbohydrate tolerance</p>
<p>Aggravation of <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p>
<p><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgias</span>; <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span></p>
<p>Changes in libido</p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></p>
<p>Anaphylactoid/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> </p>
<p><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">Exacerbation of asthma</span></p>
<p>Increased triglycerides</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_c10aac8c-51aa-457f-9029-44d8ff73a118"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE:</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing oral contraceptives by young children. Overdosage of estrogen may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_0517fb40-9590-4483-ab14-d0559add54b8"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">When estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary (see <span class="Bold">BOXED WARNINGS</span> and <span class="Bold"><a href="#i4i_warnings_id_68ce5652-ba34-4b1d-a920-22a676fc35f4">WARNINGS</a></span>). For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<p>Patients should be started at the lowest dose for the indication.</p>
<p><span class="Bold">1. For treatment of moderate to severe vasomotor symptoms, vulval and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> associated with the <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.</span></p>
<p>Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. The usual initial dosage range is 1 to 2 mg daily of estradiol adjusted as necessary to control presenting symptoms. The minimal effective dose for maintenance therapy should be determined by titration. Administration should be cyclic (e.g., 3 weeks on and 1 week off).</p>
<p><span class="Bold">2. For treatment of female hypoestrogenism due to <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span>, castration, or <span class="product-label-link" type="condition" conceptid="193739" conceptname="Ovarian failure">primary ovarian failure</span>.</span></p>
<p>Treatment is usually initiated with a dose of 1 to 2 mg daily of estradiol, adjusted as necessary to control presenting symptoms; the minimal effective dose for maintenance therapy should be determined by titration.</p>
<p><span class="Bold">3. For treatment of breast cancer, for palliation only, in appropriately selected women and men with <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</span></p>
<p>Suggested dosage is 10 mg three times daily for a period of at least three months.</p>
<p><span class="Bold">4. For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only.</span></p>
<p>Suggested dosage is 1 to 2 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient.</p>
<p><span class="Bold">5. For prevention of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>.</span></p>
<p>When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should be considered only for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and for whom non-estrogen medications are not considered to be appropriate.</p>
<p>The lowest effective dose of ESTRACE has not been determined.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_e6c3a456-9c7c-41ce-8e63-d69c8d50b68d"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First"><span class="Bold">ESTRACE<span class="Sup">Â®</span></span> (estradiol tablets, USP) are available as:</p>
<p>0.5 mg:  White to off-white, oval, flat-faced, beveled-edge, scored tablet.  Debossed with <span class="Bold">720 / Â½</span> on the scored side and <span class="Bold">WC</span> on the other side.  Available in bottles of:</p>
<p>100 Tablets NDC 0430-0720-24</p>
<p>1 mg: Light purple, oval, flat-faced, beveled-edge, scored tablet.  Debossed with<span class="Bold"> 721 / 1</span> on the scored side and <span class="Bold">WC</span> on the other side.  Available in bottles of:</p>
<p>100 Tablets NDC 0430-0721-24</p>
<p>2 mg: Green, oval, flat-faced, beveled-edge, scored tablet.  Debossed with <span class="Bold">722 / 2</span> on the scored side and <span class="Bold">WC</span> on the other side.  Available in bottles of:</p>
<p>100 Tablets NDC 0430-0722-24</p>
<p>Store at 20Âº to 25Âº C (68Âº to 77ÂºF) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.</p>
<p>Mfd by: TEVA PHARMACEUTICALS USA<br>Sellersville, PA 18960</p>
<p>Marketed by: Warner Chilcott (US), LLC</p>
<p>Rockaway, NJ 07866</p>
<p>1-800-521-8813</p>
<p>Iss. 4/2010</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5349f4f-7a27-479c-92bb-7461a42053ce"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PATIENT INFORMATION</span></h1>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ac40f4e-5fbb-4db4-a929-f794aa91adf5"></a><a name="section-13"></a><p></p>
<h1>INTRODUCTION</h1>
<p class="First">Read this PATIENT INFORMATION before you start taking ESTRACE and read what you get each time you refill ESTRACE. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<div class="Warning">
<a name="id_9f004bf1-e27d-4fb1-8cbb-960f93c199d0"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT ESTRACE (AN ESTROGEN HORMONE)?</span></p>
<ul><li>Estrogens increase the chances of getting cancer of the uterus.</li></ul>
<p>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are taking estrogens<span class="Bold">.</span> <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause. </p>
<ul><li>Do not use estrogens with or without progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>.</li></ul>
<p>Using estrogens with or without progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, and blood clots. Using estrogens with progestins may increase your risk of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. You and your healthcare provider should talk regularly about whether you still need treatment with ESTRACE. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03769ddb-d817-4aa8-8180-71162b919b16"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">WHAT IS ESTRACE?</span></h1>
<p class="First">ESTRACE is a medicine that contains estrogen hormones.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49451555-3bac-4198-96b4-356d97d337cb"></a><a name="section-15"></a><p></p>
<h1>WHAT IS ESTRACE USED FOR?</h1>
<p class="First">ESTRACE is used to:</p>
<ul><li><span class="Bold">reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> </span></li></ul>
<p>Estrogens are hormones made by a woman's ovaries. Between ages 45 and 55, the ovaries normally stop making estrogens. This leads to a drop in body estrogen levels which causes the â€œchange of lifeâ€? or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes â€œsurgical menopauseâ€?.</p>
<p>When the estrogen levels begin dropping, some women develop very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> (â€œhot flashesâ€? or â€œhot flushesâ€?). In some women, the symptoms are mild, and they will not need estrogens. In other women, symptoms can be more severe. You and your healthcare provider should talk regularly about whether you still need treatment with ESTRACE.</p>
<p>Weight-bearing exercise, like walking or running, and taking calcium with vitamin D supplements may also lower your chances for getting postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. It is important to talk about exercise and supplements with your healthcare provider before starting them. </p>
<ul><li>
<span class="Bold">treat dryness</span>, <span class="Bold"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and burning in or around the vagina, difficulty or burning on urination associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span></span>
</li></ul>
<p>You and your healthcare provider should talk regularly about whether you still need treatment with ESTRACE to control these problems. If you use ESTRACE only to treat your dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and burning in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.</p>
<ul>
<li><span class="Bold">treat certain conditions in which a young woman's ovaries do not produce enough estrogen naturally</span></li>
<li><span class="Bold">treat certain types of abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> due to hormonal imbalance when your doctor has found no serious cause of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></li>
<li><span class="Bold">treat certain cancers in special situations, in men and women</span></li>
<li><span class="Bold">prevent thinning of bones</span></li>
</ul>
<p><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> is a thinning of the bones that makes them weaker and easier to break. If you use ESTRACE only to prevent <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> from <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. You and your healthcare provider should talk regularly about whether you should continue with ESTRACE. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d2276fc-3b7f-4220-9b08-8b7f66c370be"></a><a name="section-16"></a><p></p>
<h1>WHO SHOULD NOT USE ESTRACE?</h1>
<p class="First">Do not start taking ESTRACE if you:</p>
<ul><li><span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> which has not been evaluated by your doctor (see BOXED WARNINGS)</span></li></ul>
<p>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> can be a warning sign of cancer of the uterus, especially if it happens after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. Your doctor must find out the cause of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> so that he or she can recommend the proper treatment. Taking estrogens without visiting your doctor can cause you serious harm if your <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> is caused by cancer of the uterus. </p>
<ul><li><span class="Bold">currently have or have had certain cancers</span></li></ul>
<p>Estrogens may increase the risk of certain types of cancer, including cancer of the breast or uterus. If you have or had cancer, talk with your healthcare provider about whether you should take ESTRACE.</p>
<p>(For certain patients with breast or prostate cancer, estrogens may help.)</p>
<ul>
<li><span class="Bold">had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year</span></li>
<li><span class="Bold">currently have or have had blood clots</span></li>
<li><span class="Bold">have or have had liver problems</span></li>
<li><span class="Bold">are allergic to ESTRACE or any of its ingredients</span></li>
</ul>
<p>See the end of this leaflet for a list of ingredients in ESTRACE. </p>
<p>ESTRACE 2 mg tablets contain tartrazine which may cause allergic-type reactions (including bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>) in certain susceptible individuals. Although the overall incidence of FD&amp;C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
<ul><li><span class="Bold">think you may be pregnant </span></li></ul>
<p>Tell your healthcare provider:</p>
<ul><li><span class="Bold">if you are breast feeding</span></li></ul>
<p>The hormone in ESTRACE can pass into your milk</p>
<ul><li><span class="Bold">about all of your medical problems</span></li></ul>
<p>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</p>
<ul><li><span class="Bold">about all the medicines you take</span></li></ul>
<p>This includes prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how ESTRACE works. ESTRACE may also affect how your other medicines work.</p>
<ul><li><span class="Bold">if you are going to have surgery or will be on bed rest</span></li></ul>
<p>You may need to stop taking estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58160c0a-d6a0-48a1-b6c6-23a216b3a8be"></a><a name="section-17"></a><p></p>
<h1>HOW SHOULD I TAKE ESTRACE?</h1>
<p class="First">1. Start at the lowest dose and talk to your healthcare provider about how well that dose is working for you.</p>
<p>2. Estrogens should be used at the lowest dose possible for your treatment only as long as needed. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about the dose you are taking and whether you still need treatment with ESTRACE.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_09b15769-853b-4d22-9ffe-b15716b0622b"></a><a name="section-17.1"></a><p></p>
<h2>WHAT ARE THE POSSIBLE SIDE EFFECTS OF ESTROGENS?</h2>
<p class="First"><span class="Bold">Less common but serious side effects include</span>:</p>
<ul>
<li>Breast cancer</li>
<li>Cancer of the uterus</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span></li>
<li>Blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></li>
<li>Ovarian cancer</li>
</ul>
<p><span class="Bold">These are some of the warning signs of the serious side effects</span>:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span></li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and faintness</li>
<li>Changes in speech</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Shortness of breath</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in your legs</li>
<li>Changes in vision</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
</ul>
<p>Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.</p>
<p><span class="Bold">Common side effects include</span>:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></li>
<li>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting</li>
<li>Stomach/<span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Hair loss</span></li>
</ul>
<p><span class="Bold">Other side effects include</span>:</p>
<ul>
<li>High blood pressure</li>
<li>Liver problems</li>
<li>High blood sugar</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></li>
<li>Enlargement of benign tumors (â€œfibroidsâ€?) of the uterus</li>
<li>A spotty darkening of the skin, particularly on the face</li>
<li>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></li>
</ul>
<p>These are not all the possible side effects of ESTRACE. For more information, ask your healthcare provider or pharmacist.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_69326f77-d218-4d4f-8797-2222c8054f47"></a><a name="section-18"></a><p></p>
<h1>WHAT CAN I DO TO LOWER MY CHANCES OF A SERIOUS SIDE EFFECT WITH ESTRACE?</h1>
<p class="First">If you use estrogens, you can reduce your risks by doing these things:</p>
<ul><li><span class="Bold">Talk with your healthcare provider:</span></li></ul>
<p>1. While you are using estrogens, it is important to visit your doctor at least once a year for a check-up. </p>
<p>2. If you have a uterus, talk to your healthcare provider about whether the addition of a progestin is right for you. </p>
<p>3. See your healthcare provider right away if you have <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking ESTRACE.</p>
<p>4. Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram (breast x-ray), you may need to have more frequent breast examinations. </p>
<p>5. If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease.</p>
<p>6. Talk with your healthcare provider regularly about whether you should continue taking ESTRACE. You and your doctor should reevaluate whether or not you still need estrogens at least every six months. </p>
<ul><li><span class="Bold">Be alert for signs of trouble</span></li></ul>
<p>If any of these warning signals (or any other unusual symptoms) happen while you are using estrogens, call your doctor immediately:</p>
<p>Abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina (possible uterine cancer)</p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pains</span> in the calves or chest, sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">coughing blood</span> (possible clot in the legs, or lungs)</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, faintness, changes in vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> of an arm or leg (possible clot in the brain or eye)</p>
<p><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (possible breast cancer; ask your doctor or health professional to show you how to examine your breasts monthly)</p>
<p>Yellowing of the skin or eyes (possible liver problem)</p>
<p><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the abdomen (possible gallbladder problem) </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb533aaf-52b4-4425-ba41-313908df9228"></a><a name="section-19"></a><p></p>
<h1>GENERAL INFORMATION ABOUT SAFE AND EFFECTIVE USE OF ESTRACE</h1>
<p class="First">Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take ESTRACE for conditions for which it was not prescribed. Do not give ESTRACE to other people, even if they have the same symptoms you have. It may harm them.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a95d922-d2cf-45fe-8367-8050808db235"></a><a name="section-20"></a><p></p>
<h1>KEEP ESTRACE OUT OF THE REACH OF CHILDREN</h1>
<p class="First">This leaflet provides a summary of the most important information about ESTRACE. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about ESTRACE that is written for health professionals. You can get more information by calling the toll free number 1-800-521-8813.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_993ded39-1597-4520-9975-101ff0b795c1"></a><a name="section-21"></a><p></p>
<h1>WHAT ARE THE INGREDIENTS IN ESTRACE?</h1>
<p class="First"><span class="Bold">Inactive Ingredients:</span> Colloidal silicon dioxide, corn starch, dibasic calcium phosphate, lactose monohydrate, magnesium stearate, and sodium starch glycolate. In addition, the 1 mg also contains FD&amp;C blue no. 1 aluminum lake and D&amp;C red no. 27 aluminum lake. The 2 mg also contains FD&amp;C blue no. 1 aluminum lake and FD&amp;C yellow no. 5 (tartrazine) aluminum lake.</p>
<p>Mfd by: TEVA PHARMACEUTICALS USA<br>Sellersville, PA 18960</p>
<p>Marketed by: Warner Chilcott (US), LLC</p>
<p>Rockaway, NJ 07866</p>
<p>1-800-521-8813</p>
<p>Iss. 4/2010</p>
<p>11001648</p>
<p>0720G022</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_515cd85d-c42a-439f-8965-9195ffc66858"></a><a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Estrace Tablets USP 0.5 mg 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc&amp;name=049c9f13-fc5b-417b-b686-403f17052eae-04.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0b53cd37-bf18-4483-bf71-5dba7edf5892"></a><a name="section-22.1"></a><p></p>
<h2>Estrace Tablets USP 0.5 mg 100s Label Text</h2>
<p class="First"><span class="Bold">N</span> 0430-<span class="Bold">0720</span>-24</p>
<p><span class="Bold">ESTRACE<span class="Sup">Â®</span></span><span class="Bold">TABLETS<br></span><span class="Bold">(estradiol tablets,USP)</span></p>
<p><span class="Bold">0.5 mg</span></p>
<p>PHARMACIST: Dispense <br>the accompanying Patient <br>Information Sheet to each <br>patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold"><span class="Italics">WARNER CHILCOTT</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_95b6b634-ac3c-4f20-ba82-1f330e2a9ad9"></a><a name="section-23"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Estrace Tablets USP 1 mg 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc&amp;name=049c9f13-fc5b-417b-b686-403f17052eae-02.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_41ea7a11-d10c-4cde-a458-2dfc31a21ca4"></a><a name="section-23.1"></a><p></p>
<h2>Estrace Tablets USP 1 mg 100s Label Text</h2>
<p class="First"><span class="Bold">N</span> 0430-0721-24</p>
<p><span class="Bold">ESTRACE<span class="Sup">Â®</span></span><span class="Bold">TABLETS<br></span><span class="Bold">(estradiol tablets,USP)</span></p>
<p><span class="Bold">1 mg</span></p>
<p>PHARMACIST: Dispense <br>the accompanying Patient <br>Information Sheet to each <br>patient.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold"><span class="Italics">WARNER CHILCOTT</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_859795ed-b017-428f-832d-3d1997f978f0"></a><a name="section-24"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Estrace Tablets USP 2 mg 100s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a3803ba3-4eee-4e2e-ac8c-821a4e6720cc&amp;name=049c9f13-fc5b-417b-b686-403f17052eae-03.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9de97fe6-c1a0-4f34-a3ff-3a7ab22707df"></a><a name="section-24.1"></a><p></p>
<h2>Estrace Tablets USP 2 mg 100s Label Text</h2>
<p class="First"><span class="Bold">N</span> 0430-0722-24</p>
<p><span class="Bold">ESTRACE<span class="Sup">Â®</span></span><span class="Bold">TABLETS<br></span><span class="Bold">(estradiol tablets,USP)</span></p>
<p><span class="Bold">2 mg</span></p>
<p>PHARMACIST: Dispense <br>the accompanying Patient <br>Information Sheet to each <br>patient.</p>
<p>Contains FD&amp;C Yellow No. 5<br>(tartrazine) as a color additive.</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">100 TABLETS</span></p>
<p><span class="Bold"><span class="Italics">WARNER CHILCOTT</span></span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESTRACEÂ 		
					</strong><br><span class="contentTableReg">estradiol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0720</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">0.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">720;1;2;WC</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0720-24</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040197</td>
<td class="formItem">12/26/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESTRACEÂ 		
					</strong><br><span class="contentTableReg">estradiol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0721</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 27</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (light purple) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">721;1;WC</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0721-24</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040197</td>
<td class="formItem">12/26/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ESTRACEÂ 		
					</strong><br><span class="contentTableReg">estradiol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0722</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 5</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">722;2;WC</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0722-24</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040197</td>
<td class="formItem">12/26/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott (US), LLC
							(957203177)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>049c9f13-fc5b-417b-b686-403f17052eae</div>
<div>Set id: a3803ba3-4eee-4e2e-ac8c-821a4e6720cc</div>
<div>Version: 3</div>
<div>Effective Time: 20130925</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott (US), LLC</div></p>
</body></html>
